$RXMD - Financial Highlights for Quarter Ended Dec 31, 2020!!!!!!
Consolidated Revenue for the quarter was $10.1 million, representing an increase of 1% compared to Q4 2019.
Prescriptions filled during Q4 totaled approximately 134,000, representing an increase of 1% compared to Q4 2019.
340B revenue was approximately $879k, representing a sharp increase of 200% compared to Q4 2019.
EBITDA increased 104% to $667k in Q4 2020 when compared to the same period in 2019.
Financial Highlights for Fiscal Year Ended Dec 31, 2020
Consolidated Revenue was $40.3 million, representing an increase of 22% compared to fiscal 2019.
Prescriptions filled was approximately 530,000, representing an increase of 16% compared to fiscal 2019.
340B revenue was approximately $2.8 million, representing a sharp increase of over 300% compared to fiscal 2019.
COVID testing revenue was approximately $600K, most of which was earned in Q4 2020.
Realized positive EBITDA of $7K when compared to $479K negative EBITDA in 2019.
Cash provided by operations was $1.1 million in 2020, compared to $600K cash used in 2019.
Net Cash balances as of Dec 31, 2020 was $2.1 million vs $816K compared to 2019.
Operational Highlights for the Year Ended Dec 31, 2020
Fundamental changes in management: Alan Jay Weisberg named CEO; Cecile Munnik named CFO.
Finished year with 5-Star rating earning Humana bonus of approximately $904K.
Paid off note for the building of $300K plus interest.
Generated $700K in third-party administration fees through services provided to 340B Covered Entities.
Strong execution and pro-growth strategic path resulted in shareholder value, with RXMD shares rising more than 300% during 2020
